ECSP066711A - Moduladores del receptor selectivo del estrogeno para el tratamiento de sintomas vasomotores - Google Patents

Moduladores del receptor selectivo del estrogeno para el tratamiento de sintomas vasomotores

Info

Publication number
ECSP066711A
ECSP066711A EC2006006711A ECSP066711A ECSP066711A EC SP066711 A ECSP066711 A EC SP066711A EC 2006006711 A EC2006006711 A EC 2006006711A EC SP066711 A ECSP066711 A EC SP066711A EC SP066711 A ECSP066711 A EC SP066711A
Authority
EC
Ecuador
Prior art keywords
strogen
modulators
treatment
vasomotor symptoms
selective receptor
Prior art date
Application number
EC2006006711A
Other languages
English (en)
Inventor
Jeffrey Alan Dodge
Robert Dean Dally
Scott Alan Frank
Timothy Alan Shepherd
Owen Brendan Wallace
Ronald Jay Hinklin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP066711A publication Critical patent/ECSP066711A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un modulador selectivo del receptor de estrógeno de fórmula I: o una sal de adición de ácido farmacéutico del mismo; útil para tratar síntomas vasomotores.
EC2006006711A 2004-01-22 2006-07-19 Moduladores del receptor selectivo del estrogeno para el tratamiento de sintomas vasomotores ECSP066711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53834204P 2004-01-22 2004-01-22
US53844204P 2004-01-22 2004-01-22

Publications (1)

Publication Number Publication Date
ECSP066711A true ECSP066711A (es) 2006-10-31

Family

ID=34830456

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006711A ECSP066711A (es) 2004-01-22 2006-07-19 Moduladores del receptor selectivo del estrogeno para el tratamiento de sintomas vasomotores

Country Status (20)

Country Link
US (2) US20090023917A1 (es)
EP (1) EP1709021B1 (es)
JP (1) JP4909086B2 (es)
KR (2) KR101008804B1 (es)
CN (1) CN102250042A (es)
AT (1) ATE476428T1 (es)
AU (1) AU2005207821B2 (es)
BR (1) BRPI0506721A (es)
CA (1) CA2551956C (es)
CR (1) CR8517A (es)
DE (1) DE602005022673D1 (es)
EA (2) EA012262B1 (es)
EC (1) ECSP066711A (es)
ES (1) ES2347973T3 (es)
IL (1) IL176738A0 (es)
MA (1) MA28436B1 (es)
NO (1) NO20063760L (es)
SG (1) SG149867A1 (es)
UA (1) UA85862C2 (es)
WO (1) WO2005073204A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2037905B1 (en) 2006-06-23 2013-05-01 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US10144736B2 (en) * 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
KR101319675B1 (ko) * 2008-09-29 2013-10-22 일라이 릴리 앤드 캄파니 골관절염의 치료를 위한 선택적 에스트로겐 수용체 조절자
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
JP5965909B2 (ja) 2010-09-28 2016-08-10 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
FR3014437B1 (fr) * 2013-12-05 2016-12-23 Servier Lab Nouveau procede de synthese de l'agomelatine
FR3014434B1 (fr) * 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
DK3122426T3 (da) 2014-03-28 2023-04-03 Univ Duke Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
DK3321265T3 (da) 2015-03-04 2020-06-08 Gilead Sciences Inc 4,6-diamino-pyrido[3,2-d]pyrimidinforbindelser og deres udnyttelse som modulatorer af toll-lignende receptorer
KR102397890B1 (ko) 2016-06-22 2022-05-12 일립시스 파마 리미티드 Ar+ 유방암 치료 방법
CN109923106B (zh) 2016-09-02 2022-09-13 吉利德科学公司 toll样受体调节剂化合物
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
CN108675999B (zh) * 2018-05-09 2021-03-16 浙江农林大学暨阳学院 一种醋酸铜催化制备8-(9-亚砜基-10-二氢菲)喹啉类化合物的方法
AU2019297421A1 (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD 1901-2HCL
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
SG11202100145YA (en) * 2018-07-12 2021-02-25 Lilly Co Eli Selective estrogen receptor degraders
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
TW202300492A (zh) 2021-03-16 2023-01-01 美商美國禮來大藥廠 選擇性雌激素受體降解劑
US11926634B2 (en) 2022-02-01 2024-03-12 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5726186A (en) * 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
CA2213810C (en) * 1996-08-29 2006-06-06 Lewis Dale Pennington Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
CA2217810A1 (en) * 1996-10-10 1998-04-10 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
WO1999007377A1 (en) * 1997-08-07 1999-02-18 Eli Lilly And Company 1-[4-(substituted alkoxy)benzyl]naphthalene compounds having estrogen inhibitory activity
CA2490580C (en) * 2002-07-22 2012-12-11 Eli Lilly And Company Selective estrogen receptor modulators containing a naphthalene group

Also Published As

Publication number Publication date
KR100849559B1 (ko) 2008-07-31
US20110281847A1 (en) 2011-11-17
EA016613B1 (ru) 2012-06-29
US8217032B2 (en) 2012-07-10
EP1709021B1 (en) 2010-08-04
JP4909086B2 (ja) 2012-04-04
AU2005207821B2 (en) 2011-02-10
ES2347973T3 (es) 2010-11-26
CA2551956A1 (en) 2005-08-11
JP2007519721A (ja) 2007-07-19
EA200601353A1 (ru) 2007-02-27
CA2551956C (en) 2013-05-07
KR20080016755A (ko) 2008-02-21
US20090023917A1 (en) 2009-01-22
AU2005207821A1 (en) 2005-08-11
WO2005073204A1 (en) 2005-08-11
SG149867A1 (en) 2009-02-27
IL176738A0 (en) 2006-10-31
EP1709021A1 (en) 2006-10-11
UA85862C2 (uk) 2009-03-10
NO20063760L (no) 2006-10-16
KR20060129277A (ko) 2006-12-15
BRPI0506721A (pt) 2007-05-02
DE602005022673D1 (de) 2010-09-16
CN102250042A (zh) 2011-11-23
MA28436B1 (fr) 2007-02-01
KR101008804B1 (ko) 2011-01-14
EA200900586A1 (ru) 2009-08-28
ATE476428T1 (de) 2010-08-15
EA012262B1 (ru) 2009-08-28
CR8517A (es) 2006-12-01

Similar Documents

Publication Publication Date Title
CR8517A (es) Moduladores del receptor selectivo del estrogeno para el tratamiento de sintomas vasomotores
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
BR112014019776A2 (pt) composições e métodos para o tratamento de doença vascular periférica
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
EA201000210A1 (ru) Агонисты пиридон gpr119, сопряженного с g-белком рецептора
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201190280A1 (ru) Производные l-(пиперидин-4-ил)пиразола в качестве модуляторов gpr 119
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
CL2011000544A1 (es) Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
CL2011002206A1 (es) Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EA201170043A1 (ru) Комбинация пилокарпина и метимазола для лечения заболевания шарко-мари-тута и связанных с ним нарушений
UY31922A (es) Compuestos
CL2011000341A1 (es) Compuestos derivados de pirrolidinona sustituida, moduladores de la actividad de ar para la inhibicion de ntd; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de cancer, acne, hirsutismo, entre otras.
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina